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Abstract: The dermaseptin antimicrobial peptide family contains members of 27–34 amino acids in
length that have been predominantly isolated from the skins/skin secretions of phyllomedusine leaf
frogs. By use of a degenerate primer in Rapid amplification of cDNA ends (RACE) PCR designed
to a common conserved domain within the 51-untranslated regions of previously-characterized
dermaseptin encoding cDNAs, two novel members of this peptide family, named dermaseptin-PD-1
and dermaseptin-PD-2, were identified in the skin secretion of the phyllomedusine frog, Pachymedusa
dacnicolor. The primary structures of both peptides were predicted from cloned cDNAs, as well
as being confirmed by mass spectral analysis of crude skin secretion fractions resulted from
reversed-phase high-performance liquid chromatography. Chemically-synthesized replicates of
dermaseptin-PD-1 and dermaseptin-PD-2 were investigated for antimicrobial activity using standard
model microorganisms (Gram-positive bacteria, Gram-negative bacteria and a yeast) and for
cytotoxicity using mammalian red blood cells. The possibility of synergistic effects between the two
peptides and their anti-cancer cell proliferation activities were assessed. The peptides exhibited
moderate to high inhibition against the growth of the tested microorganisms and cancer cell
lines with low haemolytic activity. Synergistic interaction between the two peptides in inhibiting
the proliferation of Escherichia coli and human neuronal glioblastoma cell line, U251MG was
also manifested.
Keywords: amphibian; peptide; antimicrobial; anticancer; molecular cloning
1. Introduction
Amphibian skins contain a well-developed chemical defense system comprised of gene-encoded
antimicrobial peptides and those with a wide range of pharmacological activities [1,2]. These peptides
are synthesized and stored in the granular glands and are released when required, usually in
response to a stressor, such as a predator attack or infection [3]. A large number of antimicrobial
peptides have been studied and it has been shown that among different amphibian species, the
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expression of antimicrobial peptides is genetically determined and that they exhibit highly-conserved
structures in their signal peptide sequences. However, each species secretes their own individual
set of antimicrobial peptides, which may only differ in a few amino acid residues within their
sequences [4,5]. These differences have been suggested to be due to the need to be effective against
diverse microorganisms in their environments [6].
To date, a large number of amphibian skin antimicrobial peptides have been identified, some of
which have demonstrated outstanding antimicrobial activities. For example, pexiganan, an analogue of
magainin 2, which is one of the first antimicrobial peptides isolated from amphibian skins, has entered
Phase III clinical trials for its antibacterial activity in the management of diabetic foot ulcers [7–10].
In addition, the bombinins, isolated from Bombina toad species, showed broad antimicrobial spectrum
while maintaining virtually inactive in haemolysis [11,12]. Additionally, brevinins, abundant in
several ranid frog species, demonstrated potent antibacterial and anticancer activities, owning to their
unique C-terminal disulfide-bridged cyclic heptapeptide, namely “rana box” [13–15]. Moreover, the
dermaseptins, isolated from the skin of South and Central American phyllomedusine leaf frogs,
exhibited broad antimicrobial spectrum with greater sensitivity to gram-negative bacteria, and
remarkably inhibitory effect against HIV infection in vitro [16–18].
The dermaseptin (DSs) family of peptides isolated from the skin secretions of phyllomedusine
frogs have been deemed interesting, since the isolation of the prototype peptide of this family,
dermaseptin s1, a 34 amino acid residue peptide from Phyllomedusa sauvagii [19], was found to have
inhibitory effects on filamentous fungi which can cause lethal infections. After this, dermaseptin
family peptides were also found to have activity against many other pathogenic microorganisms
including bacteria, yeasts and protozoans, but to have little effects on mammalian cells at effective
concentrations [16,20–22]. At present, more than 50 different dermaseptin peptides have been
identified from phyllomedusine frog species [23]. These peptides are cationic (Lys-rich) molecules
of 24–34 amino acids and have the ability to fold into amphipathic α-helical structures when being
presented in hydrophobic media [16,24]. Within their primary structures, family members also share
common signatures consisting of a conserved Trp residue at position 3 and a conserved sequence,
´AA(A/G)KAAL(G/N)A´, in their mid-regions [23]. Interestingly, although there has been intensive
study on the broad-spectrum antimicrobial activities of most dermaseptin peptides, the research on
their anticancer activity has been limited, with only two members of this family—dermaseptin B2 and
B3 having been reported to exhibit anti-proliferative activity against human prostate, mammary and
lymphoma cancer cells [25].
Here we report the isolation and characterization of two novel dermaseptins—dermaseptin-PD-1
and dermaseptin-PD-2 from the skin secretion of Pachymedusa dacnicolor. The core aim of this study was
to determine the spectrum of bioactivity of the two novel dermaseptins, including their antimicrobial
activity, both individually and in combination, and to assess their possible effects on the growth
of human cancer cell lines. Toward this goal, here we describe the cloning and sequencing of
two full-length cDNAs, each of which encodes the precursor of a novel dermaseptin antimicrobial
peptide. The cDNAs were cloned from a cDNA library constructed from the mRNAs isolated
from the lyophilized skin secretion of Pachymedusa dacnicolor. Parallelly, dermaseptin-PD-1 and
dermaseptin-PD-2 were identified in separate reversed phase HPLC fractions of the crude skin
secretion and confirmed of their primary structures by electrospray ion-trap MS/MS. Both peptides
were subsequently chemically-synthesized for antimicrobial and anti-cancer studies.
2. Results
2.1. Identification of Dermaseptin-PD-1 and Dermaseptin-PD-2 Precursor cDNAs from a Skin
Secretion-Derived cDNA Library
Two bands at approximately 300 bp and 400 bp were resolved in the gel electrophoresis following
the Rapid amplification of cDNA ends (RACE) PCR (Figure S1). Cloning of the PCR product
consistently produced two different cDNA sequences. The first cDNA encoded a precursor of a novel
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dermaseptin-related peptide named dermaseptin-PD-1 (Figure 1a) and its open reading frame consisted
of 79 amino acid residues. The second cDNA contained an open-reading frame encoding a similar
precursor to that of dermaseptin-PD-1 but consisting of 80 amino acids, including an identical signal
peptide and a similar mature peptide, which was named dermaseptin-PD-2 (Figure 1b). Both predicted
mature peptides had an identical N-terminal heptapeptide sequence—GMWSKIK—and an identical
internal motif ´AAAKE/AAAKAAGK´. Each mature peptide sequence was preceded by a Lys-Arg
motif, which is a typical endoproteolytic cleavage site. Alignment of the amino acid sequence of the
mature peptides of dermaseptin-B2, dermaseptin-PD-1 and dermaseptin-PD-2, which was performed
using Clustal tool, revealed high degree of conservation in the sequence of the three demaseptin
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acid sequences of precursors. The nucleotide sequences of mature peptides are single‐underlined, the 
nucleotide  sequences  of putative  signal peptides  are double‐underlined  and  the  stop  codons  are 
indicated by asterisks. 
 
Dermaseptin-B2        GLWSKIKEVGKEAAKAAAKAAGKAALGAVSEAV 
Dermaseptin-PD-1      GMWSKIKETAMAAAKEAAKAAGKTISDMIKQ-- 
Dermaseptin-PD-2      GMWSKIKNAGKAAAKAAAKAAGKAALDAVSEAI 
                      * *****   *** *******          
Figure 1. Nucleotide sequences of precursor cDNAs encoding dermaseptin-PD-1 (a) and dermaseptin-
PD-2 (b) cloned from a Pachymedusa dacnic lor skin se retion library and d duced amino acid sequences
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Figure 2. Alignment of amino acid sequences of dermaseptin-B2, dermaseptin-PD-1 and dermaseptin-
PD-2. The identical amino acid residues are indicated by asterisks.
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2.2. Isolation and Structural Characterisation of Dermaseptin-PD-1 and Dermaseptin-PD-2
Reversed-phase HPLC of crude skin secretion was performed to attempt identification and
structural confirmation of the putative novel dermaseptins encoded by the cloned cDNAs (Figure 3).
To this end, a sample from each chromatographic fraction was subjected to MALDI-TOF mass
spectrometric analysis. Once fractions containing peptides coincident in molecular masses to those
predicted from cloned cDNAs were identified, samples of these were further subjected to MS/MS
fragmentation sequencing. The presence and identity of both predicted peptides were confirmed.
The amino acid sequences of both peptides, as determined by MS/MS sequencing, are shown in
Tables 1 and 2. The secondary structures of both peptides, predicted using I-TASSER online server [26],
revealed that they contained a large proportion of α-helical region (Figure 4). Although the α-helical
region of dermaseptin-PD-1 is interrupted by a short coil, which consists of two amino acid residues,
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Table  1.  Predicted  b‐ion  and  y‐ion MS/MS  fragment  ion  series  (singly‐  and  doubly‐charged)  of 
dermaseptin‐PD‐1. The actual ions detected in MS/MS spectra are colored red and blue. 
#1  b(1+) b(2+)  Sequence y(1+) y(2+)  #2 
1  58.0288  29.518  G  ‐  ‐  31 
2  189.0693  95.0383  M  3207.7053  1604.3563  30 
3  375.1486  188.0779  W  3076.6648  1538.836  29 
4  462.1806  231.5939  S  2890.5855  1445.7964  28 
5  590.2756  295.6414  K  2803.5534  1402.2804  27 
6  703.3596  352.1835  I  2675.4584  1338.2329  26 
7  831.4546  416.2309  K  2562.3744  1281.6908  25 
8  960.4972  480.7522  E  2434.2794  1217.6433  24 
9  1061.5449  531.2761  T  2305.2368  1153.122  23 
10  1132.582  566.7946  A  2204.1891  1102.5982  22 
11  1263.6225  632.3149  M  2133.152  1067.0796  21 
12  1334.6596  667.8335  A  2002.1115  1001.5594  20 
13  1405.6968  703.352  A  1931.0744  966.0408  19 
14  1476.7339  738.8706  A  1860.0373  930.5223  18 
15  1604.8288  802.9181  K  1789.0002  895.0037  17 
16  1733.8714  867.4394  E  1660.9052  830.9562  16 
17  1804.9086  902.9579  A  1531.8626  766.4349  15 
18  1875.9457  938.4765  A  1460.8255  730.9164  14 
19  2004.0407  1002.524  K  1389.7883  695.3978  13 
20  2075.0778  1038.0425  A  1261.6934  631.3503  12 
21  2146.1149  1073.5611  A  1190.6563  595.8318  11 
22  2203.1364  1102.0718  G  1119.6191  560.3132  10 
23  2331.2313  1166.1193  K  1062.5977  531.8025  9 
24  2432.279  1216.6431  T  934.5027  467.755  8 
25  2545.3631  1273.1852  I  833.455  417.2311  7 
26  2632.3951  1316.7012  S  720.3709  360.6891  6 
27  2747.4221  1374.2147  D  633.3389  317.1731  5 
28  2878.4626  1439.7349  M  518.312  259.6596  4 
29  2991.5466  1496.277  I  387.2715  194.1394  3 
30  3119.6416  1560.3244  K  274.1874  137.5973  2 
31  ‐  ‐  Q‐Amidated  146.0924  73.5499  1 
Table  2.  Predicted  b‐ion  and  y‐ion MS/MS  fragment  ion  series  (singly‐  and  doubly‐charged)  of 
dermaseptin‐PD‐2. The actual ions detected in MS/MS spectra are colored red and blue. 
#1  b(1+)  b(2+) Sequence y(1+) y(2+)  #2 
1  58.0288  29.518  G  ‐  ‐  33 
Figure 4. Predicted secondary structures of (a) dermaseptin-PD-1 and (b) dermaseptin-PD-2 using
I-TASSER online server.
Table 1. Predicted b-ion and y-ion MS/MS fragment ion series (singly- and doubly-charged) of
dermaseptin-PD-1. The actual ions detected in MS/MS spectra are colored red and blue.
#1 b(1+) b(2+) Sequence y(1+) y(2+) #2
1 58.0288 29.518 G - - 31
2 189.0693 95.0383 3207.7053 1604.3563 30
3 375.1486 188.0779 3076.6648 1538.836 29
4 462.1806 231.5939 S 2890.5855 1445.7964 28
5 590.2756 295.6414 K 2803.5534 1402.2804 27
6 703.3596 352.1835 I 2675.4584 1338.2329 26
7 831.4546 416.2309 K 2562.3744 1281.6908 25
8 960.4972 480.7522 E 2434.2794 1217.6433 24
9 1061.5449 531.2761 T 2305.2368 1153.122 23
10 1132.582 566.7946 A 2204.1891 1102.5982 22
11 1263.6225 632.3149 M 2133.152 1067.0796 21
12 1334.6596 667.8335 A 2002.1115 1001.5594 20
13 140 .6968 703.352 A 1931.0744 966.04 8 19
14 147 .7339 7 8.8706 1860.0373 930.5223 18
15 1604.8288 802.9181 K 1789.0002 895.0037 17
16 1733.8714 867.4394 E 1660.9052 830.9562 16
17 1804.9086 902.9579 A 1531.8626 766.4349 15
18 1875.9457 938.4765 A 1460.8255 730.9164 14
19 200 .0407 1002.524 K 1389.7883 695.3978 13
20 2075.0778 1038.0425 A 1261.6934 631.3503 12
21 2146.1149 1073.5611 A 1190.6563 595.8318 11
22 2203.1364 1102.0718 G 1119.6191 560.3132 10
23 2331.2313 1166.1193 K 1062.5977 531.8025 9
24 2432.279 1216.6431 T 934.5027 467.755 8
25 25 5.3631 1273. 852 I 833.455 417.2311 7
26 2632.3951 1316.7012 S 720.3709 360.6891 6
27 2747.4221 1374.2147 D 633.3389 317.1731 5
28 2878.4626 1439.7349 M 518.312 259.6596 4
29 2991.5466 1496.277 I 387.2715 194.1394 3
30 3119.6416 1560.3244 K 274.1874 137.5973 2
31 - - Q-Amidated 146.0924 73.5499 1
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Table 2. Predicted b-ion and y-ion MS/MS fragment ion series (singly- and doubly-charged) of
dermaseptin-PD-2. The actual ions detected in MS/MS spectra are colored red and blue.
#1 b(1+) b(2+) Sequence y(1+) y(2+) #2
1 58.0288 29.518 G - - 33
2 189.0693 95.0383 M 3111.7462 1556.3767 32
3 375.1486 188.0779 W 2980.7057 1490.8565 31
4 462.1806 231.5939 S 2794.6263 1397.8168 30
5 590.2756 295.6414 K 2707.5943 1354.3088 29
6 703.3596 352.1835 I 2579.4993 1290.2533 28
7 831.4546 416.2309 K 2466.4153 1233.7113 27
8 945.4975 473.2524 N 2338.3203 1169.6638 26
9 1016.5347 508.771 A 2224.2774 1112.6423 25
10 1073.5561 537.2817 G 2153.2402 1077.1238 24
11 1201.6511 601.3292 K 2096.2188 1048.613 23
12 1272.6882 636.8478 A 1968.1238 984.5655 22
13 1343.7253 672.3663 A 1897.0867 949.047 21
14 1414.7625 707.8849 A 1826.0496 913.5284 20
15 1542.8574 771.9324 K 1755.0124 878.0099 19
16 1613.8946 807.4509 A 1626.9175 813.9624 18
17 1684.9317 842.9695 A 1555.8804 778.4438 17
18 1755.9688 878.488 A 1484.8432 742.9253 16
19 1884.0638 942.5355 K 1413.8061 707.4067 15
20 1955.1009 978.0541 A 1285.7111 643.3592 14
21 2026.138 1013.5726 A 1214.674 607.8407 13
22 2083.1595 1042.0834 G 1143.6369 572.3221 12
23 2211.2544 1106.1309 K 1086.6154 543.8114 11
24 2282.2916 1141.6494 A 958.5205 479.7639 10
25 2353.3287 1177.168 A 887.4833 444.2453 9
26 2466.4128 1233.71 L 816.4462 408.7268 8
27 2581.4397 1291.2235 D 703.3622 352.1847 7
28 2652.4768 1326.7421 A 588.3352 294.6712 6
29 2751.5452 1376.2763 V 517.2981 259.1527 5
30 2838.5773 1419.7923 S 418.2297 209.6185 4
31 2967.6199 1484.3136 E 331.1976 166.1025 3
32 3038.657 1519.8321 A 202.155 101.5812 2
33 - - I-Amidated 131.1179 66.0626 1
2.3. Solid Phase Synthesis of Dermaseptin-PD-1 and Dermaseptin-PD-2
After the unequivocal determination of the primary structures of dermaseptin-PD-1 and
dermaseptin-PD-2, both peptides were successfully synthesized using a solid phase Fmoc chemical
method. The synthetic peptides were then subjected to RP-HPLC to determine degree of purity and to
MALDI-TOF MS and MS/MS fragmentation to establish authenticity of structures.
2.4. Antimicrobial and Cytotoxic Activities
Dermaseptin-PD-1 exhibited a broad-spectrum of activity against all three tested microorganisms.
However, it was found to be more effective against E. coli than against either S. aureus or C. albicans.
The minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs)
obtained with this peptide are shown in Table 3. Dermaseptin-PD-2, in contrast, had an identical
antibacterial spectrum but exhibited a higher potency on all tested microorganisms (Table 3). The lethal
concentration values of dermaseptin-PD-2 on tested microorganisms are also shown in Table 2.
Both peptides did not possess significant hemolytic activity. The possible synergistic effects between
dermaseptin-PD-1 and dermaseptin-PD-2 were checked using a checkerboard assay. The combination
of both peptides showed a synergistic effect on the tested Gram-negative bacterium, E. coli at the
concentrations of 4.9 µM and 1.26 µM, respectively. The calculated lowest cumulative fractional
inhibitory concentration (ΣFIC), which is used to measure the combination effect of different
compounds, is 0.5 (Figure 5).
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Table 3. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) of the two novel peptides (dermaseptin-PD-1 and
dermaseptin-PD-2). Hemolytic effect was determined in comparison to 100% lysis of the red blood cells effected by incubation with 2% Triton X-100 for 2 h.
Peptides MIC (µM) MBC (µM) Hemolysis (µM)
E. coli S. aureus C. albicans P. aeruginosa E. coli S. aureus C. albicans P. aeruginosa Horse Red Cells
Dermaseptin-PD-1 19.6 39.2 39.2 19.6 39.2 78.4 78.4 78.4 >156.8
Dermaseptin-PD-2 5.0 5.0 10.1 2.5 20.2 10.1 20.2 10.1 >161.6
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2.5. Assessment of Activity of Peptides on Human Cancer Cell Lines
Dermaseptin-PD-1 was found to have effects in modulating the growth of H157, PC-3 and U251
MG cancer cell lines at concentrations between 10´4 and 10´9 M (Figure 6a–c). The obvious growth
inhibition of all cell lines observed with this peptide was evident above a concentration of 10´6 M.
Dermaseptin-PD-2 had more potent effects on H157 and PC-3 cells than on U251 MG cells, with IC50
values 6.43 µM, 3.17 µM, and 13.43 µM, respectively. However, dermaseptin-PD-1 only had effect on
the U251 MG cells with an IC50 value 15.08 µM and displayed no inhibition of the growth of PC-3 and
H157 cells (Figure 6d). Meanwhile, both dermaseptins showed lower cytotoxicity effect on normal
human cell line, HMEC-1 where the IC50 of dermaseptin-PD-1 and dermaseptin-PD-2 are 36.35 µM
and 27.28 µM, respectively (Figure 6e,f). The synergism study of the combination of dermaseptin-PD-1
and dermaseptin-PD-2 on human cancer cells was performed using U251 MG cell line. However, the
result only revealed an additive effect against the proliferation of U251 MG cells at the concentration
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Figure 6. The effect on proliferation of cancer cell lines, H157 (a), PC-3 (b) and U251-MG (c) after
treatment with dermaseptin-PD-2 within the concentration range of 10´9 to 10´4 M. The effect
on proliferation of cancer cell line U251 MG (d) after treatment with dermaseptin-PD-1 within the
concentration range of 10´9 to 10´4 M. The effect on normal human cell line, human microvessel
endothelial cell, HMEC-1 after treatment with dermaseptin-PD-1 (e) and dermaseptin-PD-2 (f) within
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Figure 7. The effect on proliferation of human neuronal glioblastoma cell line, U251-MG after
treatment with an array of combinations of dermaseptin-PD-1 (PD-1) and dermaseptin-PD-2 (PD-2).
The arrow indicates the highest inhibitory rate of a combination of dermaseptin-PD-1 (10 µM) and
dermaseptin-PD-2 (10 µM) and was used to calculate the combination index (Q), which is 1.086
(Q < 0.85, Q > 1.15 and 0.85 < Q < 1.15 indicate antagonism, synergy, and additive effect, respectively.)
3. Discussion
Here we report the isolation of two novel dermaseptin-like peptides from the skin secretion of
Pachymedusa dacnicolor. Dermaseptin-PD-1 with 31 residues and dermaseptin-PD-2 with 33 residues,
both display the characteristics of members of the dermaseptin family of amphibian skin antimicrobial
peptides, including several lysine residues, a conserved tryptophan residue in the third position
from the N-terminus of the mature peptide and a conserved amphipathic region in the center of
the sequence [23]. The prepropeptides of dermaseptin-PD-1 and dermaseptin-PD-2 share identity
Toxins 2016, 8, 144 10 of 16
in signal peptides and more than 80% identity in the sequences of the acidic spacer peptide regions
when maximized for sequence alignment. In addition, both prepropeptides have the highly-conserved
propeptide convertase processing sites found in other dermaseptin-family peptides [27].
The first isolation and biological evaluation of a dermaseptin peptide caused much interest,
resulting in the isolation and study of a large number of dermaseptin-family peptides from members of
the Phyllomedusinae subfamily. This was largely due to the fact that members of the dermaseptin family
have been proven to have a broad spectrum of antimicrobial activity against bacteria, yeasts, protozoans
and filamentous fungi [16,20–22]. In this report, the novel dermaseptin-like peptides described also
displayed a broad-spectrum of activity against all microorganisms tested including a Gram-positive
bacterium, a Gram-negative bacterium and a yeast. It has been found that dermaseptins can form
amphipathic α-helical structures when they associate with lipid membranes and can thus rapidly
destroy plasma membranes [24,28]. This rapid mode of action is unlikely to induce antibiotic-resistance.
Additionally, it has been documented that dermaseptins have the capacity to differentiate between
mammalian and microbial cell membranes [22], and many reports have stated that these peptides
do not show significant activity against mammalian blood cells [21,22]. The data produced in this
study in this respect also showed that these novel dermaseptins had no significant effects on horse red
blood cells. These combined properties make this group of peptides promising candidates for future
treatment of multidrug-resistant infections.
Many antimicrobial peptides display anticancer activity so that they draw much attention of
researches on anticancer drug discovery [29]. Dermaseptins have been identified since 1990s with
more than 50 analogues reported till now. In a recent study, two dermaseptin peptides, dermaseptin
B2 and B3, have been reported to be effect against the proliferation of human prostate, mammary
and lymphoma cancer cells [25]. The high degree of structural similarity between dermaseptin-PD-1,
dermaseptin-PD-2 and dermaseptin B2 (Figure 2), especially that between the latter two peptides,
may indicate similar anticancer effect of the two novel peptides, particularly on prostate cancer cells.
Interestingly, synthetic dermaseptin-PD-2 not only inhibited the proliferation of PC3 cells, but also
showed similar effect on human lung cancer cell line, H157 and neuronal glioblastoma cell line,
U251MG. However, dermaseptin-PD-1 was different in potency and spectrum of activity, which was
only effective on the proliferation of U251MG cells. In this study, dermaseptin-PD-2 showed a broader
activity spectrum than dermaseptin-PD-1 on the human cancer cell lines and both of them exhibited
low cytotoxicity on normal human cells, which makes dermaseptins more promising candidates in the
discovery of new anticancer drugs.
Many previous studies have indicated that the mechanism of action of demaseptins on cancer
cells is similar to their antimicrobial mechanisms, where electrostatic attraction plays important role
and facilitates the interaction between these cationic peptides and the negatively-charged membranes
of both microorganisms and cancer cells [29]. In this study, dermaseptin-PD-2 showed more potent
antimicrobial activity and broader spectrum on the human cancer cell lines than dermaseptin-PD-1,
which might be caused by the difference in their secondary structures. Dermaseptin-PD-2 contains one
more positive charge than dermaseptin-PD-1 in the physiological environment, which could enhance
the electrostatic attraction between the negatively-charged cell membrane and the peptides. Meanwhile,
dermaseptin-PD-2 was predicted to form a continuous and larger α-helix region while the helix of
dermaseptin-PD-1 was interrupted by a short coil (Figure 4). It is indicated that dermaseptin-PD-2
could exhibit more amphipathicity to enhance the effect on interaction between the peptide and
cell membranes.
Dermaseptin-PD-1 and dermaseptin-PD-2 showed synergistic interaction on the tested
Gram-negative bacterium, E. coli. However, there was only an additive effect of the combination
of the two peptides on human cancer cells. Yet the mechanism behind has not been investigated, it
could be explained by the natural skin defense system that is more responsible for preventing infection
of microorganism instead of cancer cells. In addition, different peptides may have special targets in the
interaction with complex cell wall and membrane of microorganisms. The synergy between different
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peptides on microorganism has also been found in other dermaseptins and other amphibian skin
peptide families, such as the bombinins from bombinid toads [4,30].
In summary, the discovery of a large number of peptides in the skin secretions of amphibians
with broad-spectrum antimicrobial bioactivity not only further highlights their role in the host defense
system, but also suggest that they might be promising candidates for the discovery of anti-infectious
agents. However, the modes of action of the peptides on both microorganism and cancer cells need to
be investigated in the future.
4. Materials and Methods
4.1. Acquisition and Maintenance of Experimental Specimens
Adult specimens of Pachymedusa dacnicolor (n = 4) were obtained from a commercial source in
the United States as small metamorphs and grown to adult size over 12 months. The frogs were
maintained in a dedicated tropical frog facility, fed multivitamin-load crickets three times per week
and at a temperature of 18–25 ˝C and 85% humidity, under a 12 h/12 h light/dark cycle. Sampling of
skin secretion was performed by Mei Zhou under UK Animal (Scientific Procedures) Act 1986,
project licence PPL 2694, issued by the Department of Health, Social Services and Public Safety,
Northern Ireland. Procedures had been vetted by the IACUC of Queen's University Belfast, and
approved on 1 March 2011.
4.2. Construction of a Skin Secretion-Derived cDNA Library and Cloning of Relevant cDNAs
Skin secretion was obtained by gently massaging the dorsal skin of the frogs. The secretion
was washed from the skin using deionized water, snap-frozen in liquid nitrogen and lyophilized.
Five milligrams of lyophilized skin secretion were dissolved in 1 mL of cell lysis/mRNA
stabilization solution supplied in the kit (Life technologies, Oslo, Norway). The isolation of
polyadenylated mRNA was achieved by using magnetic oligo-dT beads as described by the kit
manufacturer. Afterwards, 31RACE procedures were carried using a SMART-RACE kit (Clontech,
Palo Alto, CA, USA) to achieve full-length prepropeptide nucleic acid sequence data. Briefly, the
isolated mRNA was subjected to reverse transcription using a primer and reverse transcriptase
(supplied by the kit manufacturer) to obtain full-length first-strand cDNA and then 31-RACE
procedures were performed using a UPM primer supplied in the kit and a degenerate sense primer
(S1; 51-ACTTTCYGAWTTRYAAGMCCAAABATG-31) that was designed to a conserved region of the
51-untranslated region of phylloxin cDNA from Phyllomedusa bicolor (EMBL Accession no. AJ251876)
and the opioid peptide cDNA from Pachymedusa dacnicolor (EMBL Accession no. AJ005443). The PCR
procedure was carried out under the following conditions: Initial denaturation: 90 s at 94 ˝C; annealing:
30 s at 58 ˝C; extension: 180 s at 72 ˝C—for 35 cycles. PCR products were analyzed by agarose gel
electrophoresis and cloned into a pGEM-T vector system (Promega Corporation, Southampton, UK).
Sequencing reactions were performed using a BigDye Terminator sequencing kit (Applied Biosystems,
Foster City, CA, USA) and analyzed by an automated ABI 3100 DNA sequencer.
4.3. Reverse Phase HPLC Fractionation of Crude Skin Secretion and Amino-Acid Sequence Analysis of
Relevant Peptides
A further five milligrams of lyophilized skin secretion were dissolved in 0.5 mL of 0.05% (v/v)
trifluoroacetic acid (TFA)/water and clarified by centrifugation. The clear supernatant was subjected
to reverse-phase HPLC on an analytical column (Jupiter C-5, 250 mm ˆ 10 mm, Phenomenex,
Macclesfield, Cheshire, UK), eluted with a 0%–80% linear gradient of acetonitrile containing 0.05%
(v/v) TFA in 240 min at a flow rate of 1 mL/min. Absorbance was monitored at 214 nm. Fractions were
collected at minute intervals and samples from each were analyzed by matrix-assisted laser
desorption/ionization, time-of-flight mass spectrometry (MALDI-TOF MS) (Perseptive Biosystems,
Voyager DE, Perseptive Biosystems, Foster City, CA, USA). The fraction(s) containing peptides with
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molecular masse coincident with those calculated from cloned precursor-encoding cDNAs were then
subjected to MS/MS fragmentation sequencing using an electrospray ion-trap mass spectrometer
(Thermo Fisher Scientific, San Francisco, CA, USA).
4.4. Solid-Phase Peptide Synthesis
Once the primary structures of the novel peptides had been determined unequivocally, they
were separately synthesized by solid-phase Fmoc chemistry using a PS3 automated synthesizer
(Protein Technologies, Inc., Tucson, AZ, USA). Synthesis was performed using an HBTU activator,
dimethylformamide (DMF), N-methylmorpholine (NMM) and piperidine. Cleavage of the peptides
from the resin and side-chain deprotection were performed in a mixture composed of 95% TFA, 2.5%
Triisopropylsilane (TIPS), 2.5% water (v/v/v) for 6 h at room temperature. Once the peptides were
separated from the resin, they were precipitated using diethyl ether at ´20 ˝C, washed three times,
dissolved in 5 mL of 0.05% TFA/water and lyophilized. After lyophilization, the synthetic peptides
were analyzed by reverse phase HPLC and MALDI-TOF mass spectrometry for determination of
purity and authenticity of structure.
4.5. Antimicrobial Assays
The minimal inhibitory concentrations of synthetic peptides were determined using the
Gram-positive bacterium, Staphylococcus aureus (NCTC 10788), the Gram-negative bacterium,
Escherichia coli (NCTC 10418) and Pseudomonas aeruginosa (ATCC 27853), and the yeast, Candida albicans
(NCPF 1467). These four microorganisms were grown in Mueller-Hinton Broth (Oxoid, Basingstoke,
Hampshire, UK) (MHB) at 37 ˝C and optical densities (ODs) of culture media at λ550 nm were
determined to assess dilution factors required to achieve inoculation concentrations of 5 ˆ 105 colony
forming units (cfu)/mL. The highest peptide concentrations of 512 mg/L were prepared by dissolving
peptides in DMSO and dilution series were then constructed by double-dilution in culture medium.
The minimal inhibitory concentrations (MICs) were determined in 96-well microtitre plates. After the
determination of the MICs of the peptides, 10 µL of medium from each well was inoculated onto
Mueller Hinton agar (Oxoid, Basingstoke, Hampshire, UK) (MHA) plates. The minimal bactericidal
concentrations (MBC) were determined as the lowest peptide concentrations from which no colonies
were grown on the MHA plates.
4.6. Haemolysis Assay
The ability of peptides to lyse mammalian red blood cells was assessed using a 4% suspension
of horse red blood cells (supplied by TCS Biosciences Ltd, Botolph Claydon, Buckingham, UK) in
phosphate-buffered saline (PBS). The red blood cells were washed using phosphate-buffered saline
(PBS) and centrifugation, which were repeated until the supernatant was clear. A series of peptide
concentrations (512 mg/L–1 mg/L) were prepared in PBS. Five replicates of each peptide concentration
were incubated with red blood cell suspension at 37 ˝C for 2 h. After 2 h, each cell-peptide mixture
was centrifuged and 200 µL of each supernatant were added into wells of a 96-well plate. Lysis of red
blood cells was assessed by measurement of supernatant optical densities using an ELISA plate reader
(Biolise BioTek EL808, Winooski, VT, USA) set to λ550 nm. Negative controls were prepared using red
cell suspension and PBS in equal volumes. Positive controls were prepared using red cell suspension
and an equal volume of PBS containing 2% of the non-ionic detergent, Triton X-100 (Sigma-Aldrich,
St. Louis, MO, USA).
4.7. Assessment of Effects of Peptides on Human Cancer Cell Lines Using the MTT Assay
Synthetic peptides were screened for cytotoxicity on the human prostate carcinoma cell line,
PC-3 (ATCC-CRL-1435), the human non-small cell lung cancer cell line, H157 (ATCC-CRL-5802), the
human breast cancer cell line MDA-MB-435s (ATCC-HTB-129), the human neuronal glioblastoma
cell line U251MG (ECACC-09063001) and the human breast cancer non-tumorigenic mammary gland
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cell line, MCF-7 (ATCC-HTB-22). The PC-3 and H157 cell lines were cultured in RPMI-1640 culture
medium (Invitrogen, Paisley, UK) with 10% added fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis,
MO, USA) and 1% Penicillin-Streptomycin (Invitrogen, Paisley, UK), and MDA-MB-435s, U251 MG,
MCF-7 cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Invitrogen, Paisley,
UK) with 10% added FBS and 1% Penicillin-Streptomycin (Invitrogen, Paisley, UK). Meanwhile, the
cytotoxicity of synthetic peptides on normal human cell line was evaluated using human microvessel
endothelial cell, HMEC-1 (ATCC-CRL-3243), and the cells were cultured in MCDB131 medium
(Gibco, Paisley, UK) containing 10% FBS, 10 ng/mL EGF, 10 mM L-Glutamine and 1% penicillin
streptomycin. The cell lines, PC-3, H157, MDA-MB-435s and HMEC-1, were supplied by American
Type Culture Collection (ATCC, Teddington, Middlesex, UK) and U251MG was supplied by European
Collection of Authenticated Cell Cultures (ECACC, Porton Down, Salisbury, UK). When the cells
reached 80%–90% confluence, they were counted and seeded onto 96-well plates as 5000 cells in serum
medium per well. Following a 24-h incubation, the cells were treated with serum-free medium. After a
further 12 h, the cells were treated with a series of peptide concentrations (10´9–10´4 M) in serum-free
medium, with each concentration and controls in 7 replicates. The plates were incubated for a further
24 h. After this, 10 µL of MTT solution were added into each well and after a 4-h incubation, the liquid
in each well was removed and 100 µL of DMSO were added into each. The absorbance of each well
was then measured by an EL808 TM Absorbance Microplate Reader (Biolise BioTek EL808, Winooski,
VT, USA) set at 570 nm.
4.8. Assessment of Possible Synergism between the Two Peptides
The method of checkerboard titration was used to assess the possible synergistic interactions
between the peptides on both antimicrobial and anticancer activities.
According to the MIC data obtained for each peptide, peptides were prepared between
concentrations of 4 ˆMIC and 1 ˆMIC along the rows of a 96-well plate. The tested microorganism
was Escherichia coli (NCTC 10418). Microorganism culture at 106 cfu/mL, was inoculated into the
96-well plate. The plate was incubated for 18 h at 37 ˝C under humid conditions. After 18 h, optical
densities of the bacterial cultures were measured using an ELISA plate reader (Biolise BioTek EL808,
Winooski, VT, USA). The lowest cumulative fractional inhibitory concentration (ΣFIC) could then be
determined using the following formula to assess the degrees of synergy:
ΣFIC “ A{MICA ` B{MICB
where A and B represent the respective MICs when both peptides were in combination and MICA
and MICB represent the MICs for individual peptide A and peptide B. When ΣFIC ď 0.5, it indicates
synergy, whereas when 0.5 < Σ FIC ď 1, it indicates an additive effect [31,32].
For assessing the synergetic activity of two dermaseptins against the growth of cancer cell lines,
the method was modified from the previous study [33]. The tested cancer cell line was the human
neuronal glioblastoma cell line, U251MG. It was cultured and prepared as Section 4.8. After treated
with serum-free medium, three concentrations of both dermaseptins, 10 µM, 5 µM and 1 µM, were
used to set a combination array along the rows of a 96-well plate and the plate was subsequent put
into an incubator for 24 h. Then, MTT solution was added into wells followed by 4 h incubation, the
formazan crystals was dissolved by adding 100 µL of DMSO. The synergism effect of two dermaseptins
was calculated as the formula below:
Q “ Ea+b{pEa ` Eb´EaˆEbq
where Q is the combination index; Ea+b represents the cell proliferative inhibition rate of two
dermaseptins; Ea and Eb represents the cell proliferative inhibition rate for individual peptide A
and peptide B. When Q > 1.15, it indicates synergy, whereas when 0.85 < Q < 1.15, it indicates an
additive effect [33].
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Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/8/5/144/s1.
Figure S1: Gel electrophoresis of RACE PCR products from Pachymedusa dacnicolor skin secretion cDNAs library.
Data Deposition Footnote: The nucleotide sequences of clones encoding dermaseptin-PD-1 and dermaseptin-
PD-2, from the skin secretion of Pachymedusa dacnicolor, have been deposited in the EMBL Nucleotide Sequence
Database under the accession codes, LN890478 and LN890479, respectively.
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